Fulcrum Therapeutics, Inc. 8-K

What Happened

• Fulcrum Therapeutics, Inc. announced its financial results for the quarter and year ended December 31, 2025 in a press release dated February 24, 2026. The press release is furnished as Exhibit 99.1 to the Current Report on Form 8-K (Item 2.02) and is incorporated by reference.
• The Form 8-K was signed by Alex C. Sapir, President and Chief Executive Officer, on February 24, 2026.

Key Details

• Filing date: February 24, 2026 (Form 8-K).
• Period covered: quarter and fiscal year ended December 31, 2025.
• Exhibit: 99.1 — press release announcing the financial results is furnished with the 8-K.
• Cover page interactive XBRL file is included (Exhibit 104).

Why It Matters

• This 8-K tells investors that Fulcrum’s official quarterly and full‑year 2025 results are now public; the press release will contain the detailed earnings figures (revenue, net income/loss, cash position and any commentary or guidance).
• Investors should review the furnished press release and any subsequent filings (e.g., 10-K or earnings slides) for the full financial details and management discussion to assess the company’s performance and outlook.